European Joint Programme on Rare Diseases (EJP RD)

Call for Proposals 2020

"PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES"

Preliminary Announcement

The content and procedures of the call described in this pre-announcement may be subject to change and are not legally binding.

The ERA-Net E-Rare has successfully implemented ten Joint Transnational Calls for rare disease research projects since 2006. This effort continues in the framework of the European Joint Programme on Rare Diseases (EJP RD) that has been established to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC).

A number of national and regional funding organisations will participate in the EJP RD Joint Transnational Call (JTC) 2020 and will fund multilateral research projects on rare diseases together with the European Commission (EC) under the EJP-COFUND action. The call opens simultaneously with the involvement of the following funding organisations in their respective countries/regions:

- **Decision Pending:** Austrian Science Fund (FWF), Austria
- Research Foundation Flanders (FWO), Belgium, Flanders
- Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium, French-speaking community
- Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
- Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
- Ministry of Education, Youth and Sports (MEYS), Czech Republic
- Academy of Finland (AKA), Finland
- French National Research Agency (ANR), France
- French Foundation for Rare Diseases (FFRD), France
- INSERM, France (Patient Advocacy Organisations)
- Federal Ministry of Education and Research (BMBF), Germany
- **Decision Pending:** German Research Foundation (DFG), Germany
1. AIM OF THE CALL

The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear future benefit for patients.

**Topic:** PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES

Research proposals must cover at least one of the following areas:

1. Development of novel therapies in a preclinical setting (including small molecules, repurposing drugs, cell and gene advanced therapies) focusing on condition(s) with unmet medical needs
2. Use of disease models suitable for medicinal product’s development according to EMA guidelines
3. Development of predictive and pharmacodynamics (PD) biomarkers (with appropriate analytical methods e.g. OMICS) in a preclinical setting (e.g. in the validated model or in pre-collected human samples) for monitoring the efficiency of the therapy. The model chosen must mimic the human diseases and be transposable so that the biomarker identified in animals can be valid for humans
4. Proof of principle studies fostering an early (pre-clinical) stage of drug development (excluding interventional clinical trials of phase 1-4).

The following approaches and topics are excluded from the scope of the call:
a) Therapeutic approaches concerning rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases
b) Interventional clinical trials
c) Surgery or radiation therapies
d) Studies that focus on research to accelerate diagnosis or to set up new registry/cohort studies to explore disease progression and mechanisms as these were the focus of JTC 2019.
e) Rare neurodegenerative diseases which are within the main focus of the Joint Programming Initiative on Neurodegenerative Disease Research (JPND; http://www.neurodegenerationresearch.eu/). These are: Alzheimer’s disease and other dementias; Parkinson’s disease (PD) and PD-related disorders; Prion disease; Motor Neuron Diseases; Huntington’s disease; Spinal Muscular Atrophy and dominant forms of Spinocerebellar Ataxia. Interested researchers should refer to the relevant JPND calls. Childhood dementias/neurodegenerative diseases are not excluded.

**Consortium Makeup**

Projects shall involve a group of rare diseases or a single rare disease following the European definition i.e. a disease affecting not more than five in 10,000 persons in the European Community, EC associated states and Canada. Applicants are encouraged to assemble groups of rare diseases based on solid criteria and commonalities if this leverages added value in sharing resources or expertise and has the capacity to elucidate common disease mechanisms and therapeutic targets.

Partners belonging to one of the following categories may request funding under a joint research proposal (according to country/regional regulations):

- academia (research teams working in universities, other higher education institutions or research institutes),
- clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations),
- enterprises (all sizes of private companies). Participation of small and medium-sized enterprises (SMEs) is encouraged when allowed by national/regional regulations,
- patient advocacy organisations (PAOs are eligible to obtain funding for their participation in research projects).

The maximum duration of the project is three years.

Only transnational projects will be funded. Each consortium submitting a proposal must involve four to six eligible principal investigator partners. No more than two eligible partners from the same country can be present in each consortium (further national limits may apply). This limit also applies to Early Career Researchers and...
partners from underrepresented countries (see below). PAOs requesting funding do not count toward this total.

The number of partners can be increased to 8 in two cases:

- The inclusion of partners from participating countries usually underrepresented in projects (Czech Republic, Slovakia, Hungary, Lithuania, Poland, and Turkey).
- The inclusion of Early Career Researchers as full partners.

3. PRELIMINARY TIMETABLE

There will be a **two-stage submission procedure** for joint applications: pre-proposals and full proposals. The call is scheduled to open on **December 13, 2019**.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12th February 2020</td>
<td>Registration deadline</td>
</tr>
<tr>
<td>12th February 2020</td>
<td>Pre-proposal submission deadline</td>
</tr>
<tr>
<td>end April 2020</td>
<td>Invitation to full proposal</td>
</tr>
<tr>
<td>16th June 2020</td>
<td>Full proposal submission deadline</td>
</tr>
<tr>
<td>28th July 2020</td>
<td>Deadline for rebuttals</td>
</tr>
<tr>
<td>October 2020</td>
<td>Notification of funding decision</td>
</tr>
</tbody>
</table>

An independent international Scientific Evaluation Committee will carry out a scientific evaluation according to specific evaluation criteria. Based on this central evaluation, selected consortia will be invited to submit a full proposal by late **April 2020** (deadline for full proposals: **June 16th, 2020**).
Further information and the official publication of the call will soon be available on the website of the EJP RD
http://www.ejprarediseases.org

For general questions regarding the joint call please contact the Joint Call Secretariat at the ANR, France:

E-Mail: EJPRDcall@anr.fr

or individually:

Florence Guillot
florence.guillot@agencerecherche.fr
+33 (0) 1 78 09 80 01

Kiri Couchman
kiri.couchman@agencerecherche.fr
+33 (0) 1 78 09 81 29

For questions regarding national eligibility criteria and requirements please contact the national contact person listed below

The content and procedures of the call described in this pre-announcement may be subject to change and are not legally binding.

4. NATIONAL CONTACT POINTS

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Funding Organisation</th>
<th>Contact Details</th>
</tr>
</thead>
</table>
| Austria        | Austrian Science Fund (FWF)  
www.fwf.ac.at                      | Stephanie Resch
Phone: +43 (1) 505 67 40-8201
mailto:stephanie.resch@fwf.ac.at
Anita Stürtz
Phone: +43 (1) 505 67 40-8206
mailto:anita.stuertz@fwf.ac.at |
| Belgium: Flanders | Research Foundation Flanders (FWO)  
www.fwo.be                      | Alain Deleener
Phone: +32 2 550 15 95
mailto:eranet@fwo.be
Toon Monbaliu
Phone: +32 2 550 15 70
mailto:eranet@fwo.be |
<table>
<thead>
<tr>
<th>Country</th>
<th>Organization</th>
<th>Contact Person(s)</th>
</tr>
</thead>
</table>
| Belgium: French-speaking community | Fund for Scientific Research - FNRS (F.R.S.-FNRS) [www.frs-fnrs.be](http://www.frs-fnrs.be/) | Florence Quist  
Phone: +32 2 504 93 51  
mailto:florence.quist@frs-fnrs.be  
Joël Groeneveld  
Phone: +32 2 504 92 70  
mailto:joel.groeneveld@frs-fnrs.be |
| Canada                  | Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG) [www.cihr-irsc.gc.ca](http://www.cihr-irsc.gc.ca) | Jeff Warren  
Phone: +1 613 954-1964  
mailto:jeff.warren@cihr-irsc.gc.ca |
| Canada: Québec          | Fonds de recherche du Québec-Santé (FRQS) [www.frqs.gouv.qc.ca](http://www.frqs.gouv.qc.ca) | Maxime Beaudoin  
Phone: +1 514 873 2114, ext 1369  
mailto:maxime.beaudoin@frqs.gouv.qc.ca |
| Czech Republic          | Ministry of Education, Youth and Sports (MEYS) [www.msmt.cz](http://www.msmt.cz) | Daniel Hanšpach (MSMT)  
Phone: +420 234 811 360  
mailto:Daniel.Hanšpach@msmt.cz |
| Finland                 | Academy of Finland (AKA) [www.aka.fi](http://www.aka.fi)                       | Heikki Vilen  
Phone: +358 29 5335 135  
mailto:heikki.vilen@aka.fi |
Phone: +33 (0)1 78 09 80 01  
Kiri Couchman  
+33 (0) 1 78 09 81 29  
mailto:EJPRDcall@anr.fr |
| France                  | French Foundation for Rare Diseases (FFRD) [https://fondationmaladiesrares.org/eng/](https://fondationmaladiesrares.org/eng/) | Ingrid Zwaenepoel  
Phone: +33 (0) 1 58 14 22 85  
Diana Désir-Parseille  
Phone: +33 (0) 1 58 14 22 81  
mailto:gapp-bio@fondation-maladiesrares.com |
| Germany                 | Federal Ministry of Education and Research (BMBF) / Project Management Agency of the German Aerospace Centre (BMBF/ PT-DLR) [www.gesundheitsforschung-bmbf.de](http://www.gesundheitsforschung-bmbf.de) | Dr. Katarzyna Saedler  
Phone: +49 (0)228 3821 1947  
mailto:Katarzyna.Saedler@dlr.de  
Dr. Michaela Fersch  
Phone: +49 (0)228 3821 1268  
mailto:Michaela.Fersch@dlr.de  
Dr. Ralph Schuster |

EJP RD JTC 2020: Preliminary announcement
<table>
<thead>
<tr>
<th>Country</th>
<th>Organization/Contact Information</th>
<th>Phone/Fax/Email Addresses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>German Research Foundation (DFG) <a href="http://www.dfg.de">www.dfg.de</a></td>
<td>Phone: +49 (0) 228 3821 1233 <a href="mailto:Ralph.Schuster@dlr.de">mailto:Ralph.Schuster@dlr.de</a></td>
</tr>
<tr>
<td>Germany</td>
<td>Dr. Katja Großmann</td>
<td>Phone: +49 (0) 228 885 2565 Fax: +49 (0) 228 885 2777 <a href="mailto:katja.grossmann@dfg.de">mailto:katja.grossmann@dfg.de</a></td>
</tr>
<tr>
<td>Greece</td>
<td>General Secretariat for Research and Technology (GSRT) <a href="http://www.gsrt.gr">www.gsrt.gr</a></td>
<td>Sofia DIMITROPOULOU Phone: +30 2107 458 187 <a href="mailto:s.dimitropoulou@gsrt.gr">mailto:s.dimitropoulou@gsrt.gr</a></td>
</tr>
<tr>
<td>Hungary</td>
<td>National Research, Development and Innovation Office (NKFIH) <a href="http://www.nkfih.gov.hu">www.nkfih.gov.hu</a></td>
<td>Bőd Nemerkényi Phone: +36 1 8963987 <a href="mailto:elod.nemerkenyi@nkfih.gov.hu">mailto:elod.nemerkenyi@nkfih.gov.hu</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gábor Tóth Phone: +36 1 8961727 <a href="mailto:gabor.toth@nkfih.gov.hu">mailto:gabor.toth@nkfih.gov.hu</a></td>
</tr>
<tr>
<td>Ireland</td>
<td>Health Research Board (HRB) <a href="http://www.hrb.ie">https://www.hrb.ie</a></td>
<td>Louise Drudy <a href="mailto:ldrudy@hrb.ie">mailto:ldrudy@hrb.ie</a></td>
</tr>
<tr>
<td>Israel</td>
<td>Chief Scientist Office of the Ministry of Health (CSO-MOH) <a href="http://www.health.gov.il">www.health.gov.il</a></td>
<td>Irit Allon Phone: +972-2-5082167 <a href="mailto:irit.allon@moh.health.gov.il">mailto:irit.allon@moh.health.gov.il</a></td>
</tr>
<tr>
<td>Italy</td>
<td>Italian Ministry of Health (MoH-IT) <a href="http://www.salute.gov.it">www.salute.gov.it</a></td>
<td>Dr. Gaetano Guglielmi Phone: + 39 06 5994 2197 <a href="mailto:g.guglielmi@sanita.it">mailto:g.guglielmi@sanita.it</a> <a href="mailto:research.EU.dgric@sanita.it">mailto:research.EU.dgric@sanita.it</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Monica Paganelli Phone: +39 06 5994 2408 <a href="mailto:m.paganelli@sanita.it">mailto:m.paganelli@sanita.it</a></td>
</tr>
<tr>
<td>Italy</td>
<td>Ministry of Education, Universities and Research (MIUR) <a href="http://www.ricercainterazionale.miur.it">http://www.ricercainterazionale.miur.it</a></td>
<td>Aldo Covello Phone: +39 06.5849.6465 <a href="mailto:aldo.covello@miur.it">mailto:aldo.covello@miur.it</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maria Bianco Phone: +39 06.5849.7146 <a href="mailto:maria.bianco@miur.it">mailto:maria.bianco@miur.it</a></td>
</tr>
<tr>
<td>Italy: Lombardy</td>
<td>Fondazione Regionale per la Ricerca Biomedica (FRRB) <a href="http://www.frrb.it">www.frrb.it</a></td>
<td>Miss Paola Bello Mrs. Carmen De Francesco Dr. Paola Larghi, PhD <a href="mailto:bandi@frrb.it">mailto:bandi@frrb.it</a></td>
</tr>
<tr>
<td>Country</td>
<td>Organization</td>
<td>Contact Person</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Italy</td>
<td>Tuscany Region (RT/TuscReg)</td>
<td>Donatella Tanini</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Teresa Vieri</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lithuania</td>
<td>Research Council of Lithuania (RCL)</td>
<td>Dr. Živilé Ruželé</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>National Research Fund (FNR)</td>
<td>Dr. Sean Sapcariu</td>
</tr>
<tr>
<td>Poland</td>
<td>National Centre for Research and Development (NCBR)</td>
<td>Marcin Chmielewski</td>
</tr>
<tr>
<td>Portugal</td>
<td>The Foundation for Science and Technology (FCT)</td>
<td>Anabela Isidro</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rita Cavaleiro</td>
</tr>
<tr>
<td>Slovakia</td>
<td>Slovak Academy of Sciences (SAS)</td>
<td>Zuzana Cernakova, PhD.</td>
</tr>
<tr>
<td>Spain</td>
<td>National Institute of Health Carlos III (ISCIII)</td>
<td>María Druet</td>
</tr>
<tr>
<td>Sweden</td>
<td>Swedish Research Council (SRC)</td>
<td>Malin Eklund</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Swiss National Science Foundation (SNSF)</td>
<td>Christoph Meier</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>Netherlands Organization for Health Research and Development (ZonMw)</td>
<td>Harald Moonen</td>
</tr>
<tr>
<td>Country</td>
<td>Organization</td>
<td>Contact Person</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Turkey</td>
<td>The Scientific and Technological Research Council of Turkey (TUBITAK)</td>
<td>Jale şahin</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.tubitak.gov.tr">www.tubitak.gov.tr</a></td>
<td></td>
</tr>
<tr>
<td>Multinational, for funding of PAO</td>
<td>The French National Institute of Health and Medical Research (INSERM)</td>
<td>Daria Julkowska</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.inserm.fr">www.inserm.fr</a></td>
<td></td>
</tr>
</tbody>
</table>